患者报告的对化脓性汗腺炎患者 COVID-19 疫苗接受和犹豫的影响。
Patient-reported influences on COVID-19 vaccine acceptance and hesitancy in people with hidradenitis suppurativa.
机构信息
School of Medicine, University of California, San Francisco, CA, USA.
Dermatology Division, Department of Medicine, Sunnybrook Research Institute, University of Toronto, Toronto, ON, Canada.
出版信息
Br J Dermatol. 2023 Aug 24;189(3):351-353. doi: 10.1093/bjd/ljad166.
Abstract
COVID-19 continues to pose a risk to patients with hidradenitis suppurativa (HS) due to the high prevalence of comorbidities associated with severe COVID-19 disease. We aimed to characterize perspectives on COVID-19 vaccination among patients with HS. International respondents from 20 online HS support groups were recruited to complete a voluntary, anonymous, online cross-sectional survey from 25 October to 21 November 2021 to obtain perspectives from people with HS who may and may not access healthcare. We report higher rates of COVID-19 vaccine hesitancy among patients with HS who expressed dissatisfaction with their dermatological care.
摘要
由于与严重 COVID-19 疾病相关的合并症高发，COVID-19 继续对患有化脓性汗腺炎 (HS) 的患者构成威胁。我们旨在描述化脓性汗腺炎患者对 COVID-19 疫苗接种的看法。我们招募了来自 20 个在线化脓性汗腺炎支持小组的国际受访者，让他们在 2021 年 10 月 25 日至 11 月 21 日期间完成一项自愿、匿名、在线的横断面调查，以了解可能和可能无法获得医疗保健的化脓性汗腺炎患者的观点。我们报告称，对皮肤科护理不满意的化脓性汗腺炎患者对 COVID-19 疫苗的犹豫率更高。
相似文献
1
Patient-reported influences on COVID-19 vaccine acceptance and hesitancy in people with hidradenitis suppurativa.患者报告的对化脓性汗腺炎患者 COVID-19 疫苗接受和犹豫的影响。
Br J Dermatol. 2023 Aug 24;189(3):351-353. doi: 10.1093/bjd/ljad166.
2
Management of patients with hidradenitis suppurativa during COVID-19 vaccination: an experience from southern Italy. Comment on: 'Evaluating the safety and efficacy of COVID-19 vaccination in patients with hidradenitis suppurativa'.化脓性汗腺炎患者在新冠疫苗接种期间的管理：来自意大利南部的经验。评论：“评估化脓性汗腺炎患者接种新冠疫苗的安全性和有效性”
Clin Exp Dermatol. 2022 Nov;47(11):2026-2028. doi: 10.1111/ced.15306. Epub 2022 Aug 4.
3
No impact of immunomodulatory treatments on SARS-CoV-2 (COVID-19) vaccine outcomes: A cross-sectional analysis of biologic and small molecule inhibitors used for psoriasis and hidradenitis suppurativa patients from the Epic Cosmos database.免疫调节治疗对SARS-CoV-2（新冠病毒病）疫苗效果无影响：对Epic Cosmos数据库中用于银屑病和化脓性汗腺炎患者的生物制剂和小分子抑制剂的横断面分析
J Am Acad Dermatol. 2024 Jul;91(1):100-102. doi: 10.1016/j.jaad.2024.03.004. Epub 2024 Mar 13.
4
Anti-COVID-19 measurements for hidradenitis suppurativa patients.防治化脓性汗腺炎患者感染 COVID-19 的措施。
Exp Dermatol. 2021 Jun;30 Suppl 1(Suppl 1):18-22. doi: 10.1111/exd.14339.
5
Evaluating the safety and efficacy of COVID-19 vaccination in patients with hidradenitis suppurativa.评估化脓性汗腺炎患者接种新型冠状病毒疫苗的安全性和有效性。
Clin Exp Dermatol. 2022 Jun;47(6):1186-1188. doi: 10.1111/ced.15090. Epub 2022 Feb 18.
6
Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine during Ixekizumab treatment for hidradenitis suppurativa.在使用司库奇尤单抗治疗化脓性汗腺炎期间，BNT162b2 mRNA新冠疫苗的安全性和有效性。
Clin Dermatol. 2021 Jul-Aug;39(4):701-702. doi: 10.1016/j.clindermatol.2021.05.026. Epub 2021 May 19.
7
Flares and new related lesions of Hidradenitis Suppurativa following COVID-19 vaccination: A retrospective cohort study of 250 patients in Greece.新冠病毒疫苗接种后化脓性汗腺炎的发作及新的相关病变：希腊250例患者的回顾性队列研究
J Eur Acad Dermatol Venereol. 2024 Aug;38(8):e648-e650. doi: 10.1111/jdv.19968. Epub 2024 Mar 21.
8
Patient-reported outcomes in hidradenitis suppurativa.化脓性汗腺炎患者报告的结局
G Ital Dermatol Venereol. 2019 Apr;154(2):137-147. doi: 10.23736/S0392-0488.18.06021-2. Epub 2018 Oct 29.
9
Development of a patient-reported outcome questionnaire to assess signs and symptoms of hidradenitis suppurativa: The Hidradenitis Suppurativa Symptom Diary.开发一份患者报告结局问卷以评估化脓性汗腺炎的体征和症状：化脓性汗腺炎症状日记。
J Am Acad Dermatol. 2023 May;88(5):1123-1125. doi: 10.1016/j.jaad.2021.11.015. Epub 2021 Nov 19.
10
Measuring Quality of Life in Hidradenitis Suppurativa: Development and Validation of a Disease-specific Patient-reported Outcome Measure for Practice and Research.在化脓性汗腺炎中测量生活质量：用于实践和研究的疾病特异性患者报告结局测量工具的制定和验证。
Acta Derm Venereol. 2023 Jan 31;103:adv00859. doi: 10.2340/actadv.v102.2485.
引用本文的文献
1
Attitudes towards COVID Vaccine and Vaccine Hesitancy in Dermatology: A Narrative Review.皮肤病学中对新冠疫苗的态度及疫苗犹豫：一项叙述性综述
Vaccines (Basel). 2023 Aug 15;11(8):1365. doi: 10.3390/vaccines11081365.
本文引用的文献
1
Factors associated with treatment satisfaction in patients with hidradenitis suppurativa: results from the Global VOICE project.化脓性汗腺炎患者治疗满意度的相关因素：全球VOICE项目的结果
Br J Dermatol. 2022 Dec;187(6):927-935. doi: 10.1111/bjd.21798. Epub 2022 Sep 3.
2
Vaccine hesitancy and access to psoriasis care during the COVID-19 pandemic: findings from a global patient-reported cross-sectional survey.新冠疫情期间的疫苗犹豫与银屑病治疗可及性：一项全球患者报告横断面调查的结果
Br J Dermatol. 2022 Aug;187(2):254-256. doi: 10.1111/bjd.21042. Epub 2022 May 3.
3
SARS-COV-2 vaccine acceptance in patients with rheumatic diseases: a cross-sectional study.风湿性疾病患者对 SARS-CoV-2 疫苗的接受度：一项横断面研究。
Hum Vaccin Immunother. 2021 Nov 2;17(11):4048-4056. doi: 10.1080/21645515.2021.1958611. Epub 2021 Aug 6.
4
Outcomes of patients with chronic plaque psoriasis and hidradenitis suppurativa on biologic therapy during the Covid-19 pandemic: A UK dermatology tertiary centre experience.
Skin Health Dis. 2021 Jun 9;1(3):e54. doi: 10.1002/ski2.54. eCollection 2021 Sep.
5
Vaccination against COVID-19: Expectations and concerns of patients with autoimmune and rheumatic diseases.2019冠状病毒病疫苗接种：自身免疫性和风湿性疾病患者的期望与担忧
Lancet Rheumatol. 2021 Apr;3(4):e243-e245. doi: 10.1016/S2665-9913(21)00039-4. Epub 2021 Feb 22.
6
Comorbidity screening in hidradenitis suppurativa: Evidence-based recommendations from the US and Canadian Hidradenitis Suppurativa Foundations.化脓性汗腺炎的共病筛查：美国和加拿大化脓性汗腺炎基金会的循证建议
J Am Acad Dermatol. 2022 May;86(5):1092-1101. doi: 10.1016/j.jaad.2021.01.059. Epub 2021 Jan 23.
7
Evaluating patients' unmet needs in hidradenitis suppurativa: Results from the Global Survey Of Impact and Healthcare Needs (VOICE) Project.评估化脓性汗腺炎患者的未满足需求：来自全球影响和医疗需求调查（VOICE）项目的结果。
J Am Acad Dermatol. 2020 Feb;82(2):366-376. doi: 10.1016/j.jaad.2019.06.1301. Epub 2019 Jul 3.
Zotero 插件